Your browser doesn't support javascript.
loading
Age-specific predictors of disease severity in children with respiratory syncytial virus infection beyond infancy and through the first 5 years of age.
Brenes-Chacon, Helena; Eisner, Mariah; Acero-Bedoya, Santiago; Ramilo, Octavio; Mejias, Asuncion.
Affiliation
  • Brenes-Chacon H; Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Eisner M; Department of Pediatrics, Division of Infectious Diseases, Hospital Nacional de Niños Dr. Carlos Sáenz Herrera, San José, Costa Rica.
  • Acero-Bedoya S; Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Ramilo O; Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Mejias A; Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
Pediatr Allergy Immunol ; 35(2): e14083, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38363050
ABSTRACT

BACKGROUND:

Respiratory syncytial virus (RSV) infection is associated with significant morbidity in infants. Risk factors for severe disease beyond the first 2 years of life have not been fully defined.

METHODS:

Children <5 years hospitalized with virologically confirmed RSV infection were identified over six respiratory seasons (10/2012-4/2018) and their medical records manually reviewed. Multivariable analyses were performed to define the age-specific (<6, 6-24, and >24-59 months) risk factors associated with oxygen administration, PICU admission, mechanical ventilation, and duration of hospitalization.

RESULTS:

We identified 5143 children hospitalized with RSV infection 53.5% (n = 2749) <6 months; 31.7% (n = 1631) 6-24 months; and 14.8% (n = 763) >24-59 months. Rates of ICU admission were high (35%-36%) and comparable across age groups, while children >24-59 and 6-24 versus those <6 months required supplemental oxygen more frequently (73%; 71%; 68%, respectively; p = .003). The presence of comorbidities increased with age (25%, <6 months; 46%, 6-24 months; 70%, >24-59 months; p < .001). Specifically, neuromuscular disorders, chronic lung disease, and reactive airway disease/asthma were predictive of worse clinical outcomes in children aged 6-24 and >24-59 months, while RSV-viral codetections increased the risk of severe outcomes in children aged <6 and 6-24 months of age.

CONCLUSIONS:

Almost half of children hospitalized with RSV infection were >6 months. Underlying comorbidities increased with age and remained associated with severe disease in older children, while RSV-viral codetections were predictive of worse clinical outcomes in the youngest age groups. These data suggest the importance of defining the clinical phenotype associated with severe RSV according to age, and the persistent burden associated with RSV beyond infancy.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Respiratory Syncytial Virus Infections Type of study: Prognostic_studies / Risk_factors_studies Limits: Child / Child, preschool / Humans / Infant Language: En Journal: Pediatr Allergy Immunol Journal subject: ALERGIA E IMUNOLOGIA / PEDIATRIA Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Respiratory Syncytial Virus Infections Type of study: Prognostic_studies / Risk_factors_studies Limits: Child / Child, preschool / Humans / Infant Language: En Journal: Pediatr Allergy Immunol Journal subject: ALERGIA E IMUNOLOGIA / PEDIATRIA Year: 2024 Type: Article Affiliation country: United States